Literature DB >> 2346520

Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement.

S Hirohata1, T Miyamoto.   

Abstract

Paired serum and cerebrospinal fluid (CSF) specimens from 14 patients with systemic lupus erythematosus (SLE) and central nervous system (CNS) involvement were studied for interleukin-6 (IL-6) activity using the IL-6-dependent murine hybridoma, MH60.BSF2. We also studied 23 patients with noninflammatory neurologic diseases, and 9 SLE patients without CNS involvement. CSF IL-6 activity was elevated only in SLE patients with CNS involvement, although there was no significant difference in serum IL-6 activity among the 3 groups. CSF IL-6 activity was not correlated with either the CSF-serum albumin quotient (Q albumin; an indicator of blood-brain barrier function) or serum IL-6 activity in SLE patients with CNS involvement. The CSF IL-6 activity decreased significantly when CNS manifestations subsided after successful treatment. These results indicate that determination of CSF IL-6 activity may be useful in the evaluation of CNS disease activity in SLE. Moreover, the data confirm the presence of immune system activation within the CNS in patients with SLE-associated CNS disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2346520     DOI: 10.1002/art.1780330506

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  62 in total

Review 1.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  IVIg attenuates TLR-9 activation in B cells from SLE patients.

Authors:  Aharon Kessel; Regina Peri; Tharwat Haj; Ayelet Snir; Gleb Slobodin; Edmond Sabo; Itzhak Rosner; Yehuda Shoenfeld; Elias Toubi
Journal:  J Clin Immunol       Date:  2010-10-05       Impact factor: 8.317

3.  Differences in regional brain activation patterns assessed by functional magnetic resonance imaging in patients with systemic lupus erythematosus stratified by disease duration.

Authors:  Meggan Mackay; Mathew P Bussa; Cynthia Aranow; Aziz M Uluğ; Bruce T Volpe; Patricio T Huerta; Miklos Argyelan; Arthur Mandel; Joy Hirsch; Betty Diamond; David Eidelberg
Journal:  Mol Med       Date:  2011-09-21       Impact factor: 6.354

4.  A case of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with lupus erythematosus in the central nervous system.

Authors:  Hiroaki Hara; Hajime Hasegawa; Mizuki Iwanaga; Tomonya Ogawa; Akihiko Matsuda; Koichi Kanozawa; Hitoshi Kato; Tetsuya Mitarai
Journal:  CEN Case Rep       Date:  2012-08-15

5.  Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus.

Authors:  Yasuhiro Shimojima; Masayuki Matsuda; Takahisa Gono; Wataru Ishii; Shu-ichi Ikeda
Journal:  Clin Rheumatol       Date:  2005-03-02       Impact factor: 2.980

6.  Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors.

Authors:  A R Rezai; A Rezai; O Martínez-Maza; M Vander-Meyden; M H Weiss
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  C3aR inhibition reduces neurodegeneration in experimental lupus.

Authors:  A Jacob; L Bao; J Brorson; R J Quigg; J J Alexander
Journal:  Lupus       Date:  2009-11-09       Impact factor: 2.911

8.  Immunohistochemical localization of interleukin-6-like immunoreactivity to peripheral nerve-like structures in normal and inflamed human skin.

Authors:  K Nordlind; L B Chin; A A Ahmed; J Brakenhoff; E Theodorsson; S Lidén
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

Review 9.  Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Akiko Kobayashi; Hisashi Yamanaka
Journal:  J Biomed Biotechnol       Date:  2010-06-29

10.  Cytokine regulation of hemostatic property and IL-6 production of human endothelial cells.

Authors:  Y Hashimoto; S Hirohata; T Kashiwado; K Itoh; H Ishii
Journal:  Inflammation       Date:  1992-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.